These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18728023)

  • 41. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
    Williams RT; Sherr CJ
    Adv Exp Med Biol; 2007; 604():107-14. PubMed ID: 17695724
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.
    Okabe S; Tauchi T; Ohyashiki K
    Exp Hematol; 2010 Sep; 38(9):765-72. PubMed ID: 20471447
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia.
    Hallböök H; Barbany G; Aleskog A; Björnberg A; Larsson R; Sundström C; Lindhagen E
    Anticancer Drugs; 2005 Jul; 16(6):631-4. PubMed ID: 15930891
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.
    Gambacorti-Passerini CB; Gunby RH; Piazza R; Galietta A; Rostagno R; Scapozza L
    Lancet Oncol; 2003 Feb; 4(2):75-85. PubMed ID: 12573349
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.
    Ernst T; Hoffmann J; Erben P; Hehlmann R; Hochhaus A; Müller MC
    Clin Chem Lab Med; 2008; 46(3):318-22. PubMed ID: 18303987
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytogenetic and molecular mechanisms of resistance to imatinib.
    Hochhaus A
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):69-79. PubMed ID: 12783379
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.
    Irving JA; O'Brien S; Lennard AL; Minto L; Lin F; Hall AG
    Clin Chem; 2004 Jul; 50(7):1233-7. PubMed ID: 15229152
    [No Abstract]   [Full Text] [Related]  

  • 50. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
    Weisberg E; Manley PW; Breitenstein W; Brüggen J; Cowan-Jacob SW; Ray A; Huntly B; Fabbro D; Fendrich G; Hall-Meyers E; Kung AL; Mestan J; Daley GQ; Callahan L; Catley L; Cavazza C; Azam M; Neuberg D; Wright RD; Gilliland DG; Griffin JD
    Cancer Cell; 2005 Feb; 7(2):129-41. PubMed ID: 15710326
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
    Roumiantsev S; Shah NP; Gorre ME; Nicoll J; Brasher BB; Sawyers CL; Van Etten RA
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10700-5. PubMed ID: 12149456
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Janus kinase 2: a critical target in chronic myelogenous leukemia.
    Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
    Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.
    Aloisi A; Di Gregorio S; Stagno F; Guglielmo P; Mannino F; Sormani MP; Bruzzi P; Gambacorti-Passerini C; Saglio G; Venuta S; Giustolisi R; Messina A; Vigneri P
    Blood; 2006 Feb; 107(4):1591-8. PubMed ID: 16249386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
    Williams RT; Roussel MF; Sherr CJ
    Proc Natl Acad Sci U S A; 2006 Apr; 103(17):6688-93. PubMed ID: 16618932
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Substances from the medicinal mushroom Daedalea gibbosa inhibit kinase activity of native and T315I mutated Bcr-Abl.
    Yassin M; Wasser SP; Mahajna J
    Int J Oncol; 2008 Jun; 32(6):1197-204. PubMed ID: 18497981
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.
    Hofmann WK; Jones LC; Lemp NA; de Vos S; Gschaidmeier H; Hoelzer D; Ottmann OG; Koeffler HP
    Blood; 2002 Mar; 99(5):1860-2. PubMed ID: 11861307
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.
    Yoshida C; Melo JV
    Int J Hematol; 2004 Jun; 79(5):420-33. PubMed ID: 15239391
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation.
    Cebo C; Da Rocha S; Wittnebel S; Turhan AG; Abdelali J; Caillat-Zucman S; Bourhis JH; Chouaib S; Caignard A
    J Immunol; 2006 Jan; 176(2):864-72. PubMed ID: 16393970
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia.
    Inami M; Inokuchi K; Nakayama K; Tamura H; Shimada T; Dan K
    Int J Hematol; 2003 Aug; 78(2):173-5. PubMed ID: 12953816
    [No Abstract]   [Full Text] [Related]  

  • 60. A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment.
    von Bubnoff N; Barwisch S; Speicher MR; Peschel C; Duyster J
    Cell Cycle; 2005 Mar; 4(3):400-6. PubMed ID: 15738656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.